Eli Lilly and NVIDIA are collaborating to build the most powerful supercomputer owned and operated by a pharmaceutical company[1][2][3]. The supercomputer is powered by more than 1000 NVIDIA B300 GPUs or 1016 NVIDIA Blackwell Ultra GPUs and serves as an "AI factory" for the entire life cycle of artificial intelligence[1][3][5][6]. Scientists will use it to train AI models on millions of experiments to test potential drugs, expanding drug discovery[1][3][5]. These models will be available on the Lilly TuneLab platform, which is based on a $1 billion investment and will provide access to biotech companies in exchange for training data[3][5][6]. The supercomputer will accelerate drug development, shorten development cycles, support medical imaging, production and AI agents[3][5]. It will run on 100% renewable electricity in liquid-cooled Lilly facilities[1][5]. The collaboration is part of Lilly's plan to invest $50 billion in manufacturing and research in the US[6]. The supercomputer is scheduled to be launched in January 2026[4].